uniQure Q3 2022 Earnings Report

uniQure reported its Q3 2022 financial results and highlighted recent company progress.

Key Takeaways

uniQure's Q3 2022 collaboration revenue was $1.4 million, R&D expenses were $48.1 million, and SG&A expenses were $13.3 million. The company's net loss for the quarter was $47.9 million, or $1.02 per share. As of September 30, 2022, the company held $440.3 million in cash and cash equivalents.

Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Board recommendation.

U.S. and European pre-approval inspections of Company’s Lexington, MA manufacturing site completed with EMA issuing Good Manufacturing Certificate.

Virtual investor event focused on next pipeline program, AMT-260 investigational gene therapy for refractory temporal lobe epilepsy, to be held on Tuesday, November 29, 2022

Company held cash and cash equivalents of $440.3 million as of September 30, 2022.

Total Revenue

$1.45M

Previous year: $1.99M

-27.1%

EPS

-$1.02

Previous year: -$0.79